Advances in clinical research on vascular interventional therapy for hepatocellular carcinoma

Liangzhi WEN; Xiao XIAO; Qixian YAN; Jun WANG

doi:10.3969/j.issn.1001-5256.2021.08.005

Volume 37 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(8): 1761-1764

PDF( 1872 KB)

Advances in clinical research on vascular interventional therapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.08.005

Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400042, China

Research funding:

Science and Technology Innovation Ability Enhancement Special Project of Army Military Medical University (2019XLC3045);

National Natural Science Foundation of China (81802459);

Natural Science Foundation of Chongqing (cstc2018jcyjAX0603)

Received Date: 2021-05-28
Accepted Date: 2021-05-28
Published Date: 2021-08-20

Abstract

Abstract

Vascular interventional therapy for hepatocellular carcinoma (HCC) is the most important treatment modality for unresectable HCC, including transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy. With the development and application of new materials and surgical procedures, the above treatment regimens have been modified and optimized, and various clinical studies have discussed the clinical effect of different regimens in the treatment of HCC and have made new achievements, which provides new strategies and a theoretical basis for vascular interventional therapy for HCC in clinical practice. This article summarizes the new advances in the clinical research on vascular interventional therapy for HCC.
- Carcinoma, Hepatocellular,
- Chemoembolization, Therapeutic,
- Chemotherapy, Cancer, Regional Perfusion

FullText(HTML)

References(33)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001.
[3]	MALUCCIO M, COVEY A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin, 2012, 62(6): 394-399. DOI: 10.3322/caac.21161.
[4]	BREEDIS C, YOUNG G. The blood supply of neoplasms in the liver[J]. Am J Pathol, 1954, 30(5): 969-977.
[5]	LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739. DOI: 10.1016/S0140-6736(02)08649-X.
[6]	LO CM, NGAN H, TSO WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5): 1164-1171. DOI: 10.1053/jhep.2002.33156.
[7]	GOLFIERI R, GIAMPALMA E, RENZULLI M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264. DOI: 10.1038/bjc.2014.199.
[8]	FACCIORUSSO A, DI MASO M, MUSCATIELLO N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis[J]. Dig Liver Dis, 2016, 48(6): 571-577. DOI: 10.1016/j.dld.2016.02.005.
[9]	CHANG Y, JEONG SW, YOUNG JANG J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21): 8165. DOI: 10.3390/ijms21218165.
[10]	Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[11]	BARGELLINI I, SACCO R, BOZZI E, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study[J]. Eur J Radiol, 2012, 81(6): 1173-1178. DOI: 10.1016/j.ejrad.2011.03.046.
[12]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[13]	RAOUL JL, FORNER A, BOLONDI L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72: 28-36. DOI: 10.1016/j.ctrv.2018.11.002.
[14]	LIANG L, LI C, DIAO YK, et al. Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: A systematic review and meta-analysis[J]. Therap Adv Gastroenterol, 2020, 13: 1756284820977693. DOI: 10.1177/1756284820977693.
[15]	WANG Z, REN Z, CHEN Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: A randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899.
[16]	LOPEZ-LOPEZ V, ROBLES-CAMPOS R, BRUSADIN R, et al. ALPPS for hepatocarcinoma under cirrhosis: A feasible alternative to portal vein embolization[J]. Ann Transl Med, 2019, 7(22): 691. DOI: 10.21037/atm.2019.10.57.
[17]	TRUTY MJ, VAUTHEY JN. Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma[J]. Semin Oncol, 2010, 37(2): 102-109. DOI: 10.1053/j.seminoncol.2010.03.013.
[18]	ZHANG CW, DOU CW, ZHANG XL, et al. Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy[J]. World J Gastroenterol, 2020, 26(30): 4489-4500. DOI: 10.3748/wjg.v26.i30.4489.
[19]	KUDO M, ARIZUMI T, UESHIMA K. Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology, 2014, 59(6): 2424-2425. DOI: 10.1002/hep.26760.
[20]	KLOECKNER R, PITTON MB, DUEBER C, et al. Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2017, 28(1): 94-102. DOI: 10.1016/j.jvir.2016.06.012.
[21]	SALEM R, LEWANDOWSKI R, ROBERTS C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis[J]. J Vasc Interv Radiol, 2004, 15(4): 335-345. DOI: 10.1097/01.rvi.0000123319.20705.92.
[22]	MIKELL JK, DEWARAJA YK, OWEN D. Transarterial radioembolization for hepatocellular carcinoma and hepatic metastases: Clinical aspects and dosimetry models[J]. Semin Radiat Oncol, 2020, 30(1): 68-76. DOI: 10.1016/j.semradonc.2019.08.005.
[23]	VILGRAIN V, PEREIRA H, ASSENAT E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636. DOI: 10.1016/S1470-2045(17)30683-6.
[24]	SALEM R, GORDON AC, MOULI S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163. e2. DOI: 10.1053/j.gastro.2016.08.029.
[25]	SALEM R, GABR A, RIAZ A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1, 000-patient 15-year experience[J]. Hepatology, 2018, 68(4): 1429-1440. DOI: 10.1002/hep.29691.
[26]	ANDO E, TANAKA M, YAMASHITA F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases[J]. Cancer, 2002, 95(3): 588-595. DOI: 10.1002/cncr.10694.
[27]	KUDO M, MATSUI O, IZUMI N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3(3-4): 458-468. DOI: 10.1159/000343875.
[28]	LYU N, LIN Y, KONG Y, et al. FOXAI: A phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396. DOI: 10.1136/gutjnl-2017-314138.
[29]	LYU N, KONG Y, MU L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69. DOI: 10.1016/j.jhep.2018.02.008.
[30]	HE MK, LE Y, LI QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83. DOI: 10.1186/s40880-017-0251-2.
[31]	HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
[32]	MEI J, TANG YH, WEI W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 618206. DOI: 10.3389/fonc.2021.618206.
[33]	SAEKI I, YAMASAKI T, MAEDA M, et al. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(3): e87-e97. DOI: 10.1111/hepr.12932.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(13)

1.	温芳芳，张龙，王娟. 预后营养指数、血清白蛋白对肝切除术病人术后感染风险的预测价值及护理指导意义. 全科护理. 2025(02): 236-239 .
2.	魏红艳，王远珍，常丽仙，木唤，刘春云，刘立. 原发性肝癌合并腹水患者发生SBP的风险预测分析. 昆明医科大学学报. 2024(03): 133-140 .
3.	魏红艳，王远珍，常丽仙，木唤，刘春云，刘立. 原发性肝癌患者并发自发性腹膜炎临床诊断模型的构建和应用. 现代肿瘤医学. 2024(19): 3718-3725 .
4.	朱明强，杨大帅，熊祥云，裴俊鹏，彭阳，丁佑铭. 肝癌肝切除术后感染风险预测模型的建立与评价. 临床肝胆病杂志. 2023(01): 110-117 . 本站查看
5.	罗清兰，邓宇伟，曾涛. 原发性肝癌术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和甲胎蛋白对预后的评估分析. 当代医学. 2022(19): 18-21 .
6.	付先锋，晏燕. 肝动脉介入栓塞治疗的肝癌患者预后与血清胆碱酯酶、钠水平的关系分析. 检验医学与临床. 2022(24): 3417-3420 .
7.	曾桥. 腹腔镜手术治疗肝癌的分析. 当代医学. 2021(04): 96-98 .
8.	黄旦华. 多项肿瘤标志物联合检测在肝癌中的诊断效能. 医疗装备. 2021(11): 52-53 .
9.	袁维，孙克伟，陈斌，朱文芳，银思涵. 56例中晚期原发性肝癌死亡患者的临床分析. 中西医结合肝病杂志. 2021(08): 707-711 .
10.	马冰，白黎，赵艳，海丹丹，李花花. 原发性肝癌TACE术后发生感染性并发症的影响因素研究. 实用癌症杂志. 2021(12): 2033-2035 .
11.	王益卓，刘唯佳，卢兵，黄其密，唐德奉. 原发性肝癌合并肺部感染58例临床特征分析. 中华肺部疾病杂志(电子版). 2020(01): 83-84 .
12.	刘娟. 以坚强概念为基础的心理干预对原发性肝癌合并抑郁病人症状改善、心理状态及生命质量的影响. 全科护理. 2020(28): 3834-3837 .
13.	叶颖剑，刘波，陈伟，李琼霞. 血清AFP阴性的肝细胞癌患者预后及分期系统分析. 临床肝胆病杂志. 2019(03): 535-541 . 本站查看

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (771) PDF downloads(131)

Advances in clinical research on vascular interventional therapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.08.005